Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney

Kidney International

Volumn 88, Issue 6, 2015, Pages 1261-1273

  Shelton, Luke M ^a   Lister, Adam ^b   Walsh, Joanne ^a   Jenkins, Rosalind E ^a   Wong, Michael H L ^a   Rowe, Cliff ^a,c   Ricci, Emanuele ^a   Ressel, Lorenzo ^a   Fang, Yongxiang ^a   Demougin, Philippe ^d   Vukojevic, Vanja ^d   O'Neill, Paul M ^a   Goldring, Christopher E ^a   Kitteringham, Neil R ^a   Park, B Kevin ^a   Odermatt, Alex ^b   Copple, Ian M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

ITRAQ; Keap1; Nrf2; Oxidative stress; ROS

Indexed keywords

BARDOXOLONE METHYL; CYTOCHROME P450 2A5; GLUCURONOSYLTRANSFERASE 1A10; GLUTATHIONE; GLUTATHIONE TRANSFERASE A3; GLUTATHIONE TRANSFERASE M1; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTOME;

ABCC2 GENE; ALDH1 GENE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYP2A5 GENE; DPYS GENE; EXTRACELLULAR SPACE; GCLM GENE; GENE; GENE ACTIVITY; GSTA3 GENE; GSTM1 GENE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; KNOCKOUT MOUSE; MALE; MOUSE; NAMPT GENE; NONHUMAN; NQO1 GENE; NRF2 GENE; OXIDATION REDUCTION REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SLC35E3 GENE; SPATC1 GENE; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UGT1A10 GENE; XENOBIOTIC METABOLISM;

EID: 84951569035     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.286     Document Type: Article

References (51)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936
2. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006; 2: 80-91
3. Aleksunes LM, Goedken MJ, Rockwell CE et al. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 2010; 335: 2-12
4. Umemura T, Sai K, Takagi A et al. Oxidative DNA damage, lipid peroxidation and nephrotoxicity induced in the rat kidney after ferric nitrilotriacetate administration. Cancer Lett 1990; 54: 95-100
5. Jiang T, Huang ZP, Lin YF et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59: 850-860
6. Bryan HK, Olayanju A, Goldring CE et al. The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem Pharmacol 2013; 85: 705-717
7. Copple IM. The Keap1-Nrf2 cell defense pathway-a promising therapeutic target? Adv Pharmacol 2012; 63: 43-79
8. Pergola PE, Krauth M, Huff JW et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2011; 33: 469-476
9. de Zeeuw D, Akizawa T, Audhya P et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503
10. Chin MP, Reisman SA, Bakris GL et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 2014; 39: 499-508
11. Kitteringham NR, Abdullah A, Walsh J et al. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics 2010; 73: 1612-1631
12. Enomoto A, Itoh K, Nagayoshi E et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001; 59: 169-177
13. Liu J, Wu KC, Lu YF et al. Nrf2 protection against liver injury produced by various hepatotoxicants. Oxid Med Cell Longev 2013; 2013: 305861
14. Walsh J, Jenkins RE, Wong M et al. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications. J Proteomics 2014; 108: 171-187
15. Shelton LM, Park BK, Copple IM. Role of Nrf2 in protection against acute kidney injury. Kidney Int 2013; 84: 1090-1095
16. Leonard MO, Kieran NE, Howell K et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 2006; 20: 2624-2626
17. Liu M, Grigoryev DN, Crow MT et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009; 76: 277-285
18. Yoon HY, Kang NI, Lee HK et al. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 2008; 75: 2214-2223
19. Wu QQ, Wang Y, Senitko M et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J Physiol Renal Physiol 2011; 300: F1180-F1192
20. Elangovan S, Hsieh TC. Control of cellular redox status and upregulation of quinone reductase NQO1 via Nrf2 activation by alpha-lipoic acid in human leukemia HL-60 cells. Int J Oncol 2008; 33: 833-838
21. Malhotra D, Portales-Casamar E, Singh A et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010; 38: 5718-5734
22. Ruiz S, Pergola PE, Zager RA et al. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013; 83: 1029-1041
23. Choi BH, Kang KS, Kwak MK. Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 2014; 19: 12727-12759
24. Jeong HS, Ryoo IG, Kwak MK. Regulation of the expression of renal drug transporters in KEAP1-knockdown human tubular cells. Toxicol In Vitro 2015; 29: 884-892
25. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int 2014; 2014: 967826
26. Reisman SA, Chertow GM, Hebbar S et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663-1673
27. Xu B, Yoshida Y, Zhang Y et al. Two-dimensional electrophoretic profiling of normal human kidney: differential protein expression in glomerulus, cortex and medulla. J Electrophoresis 2005; 49: 5-13
28. Oh GS, Kim HJ, Choi JH et al. Pharmacological activation of NQO1 increases NAD levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int 2013; 85: 547-560
29. Gang GT, Kim YH, Noh JR et al. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity. Toxicol Lett 2013; 221: 165-175
30. Wu KC, Cui JY, Klaassen CD. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci 2011; 123: 590-600
31. Tanaka Y, Aleksunes LM, Goedken MJ et al. Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicol Appl Pharmacol 2008; 231: 364-373
32. Wu J, Liu X, Fan J et al. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. Toxicology 2014; 318: 22-31
33. Yates MS, Tauchi M, Katsuoka F et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007; 6: 154-162
34. Nowik M, Lecca MR, Velic A et al. Genome-wide gene expression profiling reveals renal genes regulated during metabolic acidosis. Physiol Genomics 2008; 32: 322-334
35. Busque SM, Stange G, Wagner CA. Dysregulation of the glutamine transporter Slc38a3 (SNAT3) and ammoniagenic enzymes in obese, glucose-intolerant mice. Cell Physiol Biochem 2014; 34: 575-589
36. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100
37. Small DM, Coombes JS, Bennett N et al. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 2012; 17: 311-321
38. Kim HJ, Sato T, Rodriguez-Iturbe B et al. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J Pharmacol Exp Ther 2011; 337: 583-590
39. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-F671
40. Aminzadeh MA, Nicholas SB, Norris KC et al. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant 2013; 28: 2038-2045
41. Ding Y, Stidham RD, Bumeister R et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int 2013; 83: 845-854
42. Vaziri ND, Liu S, Farzaneh SH et al. Dose-dependent deleterious and salutary actions of Nrf2 inducer, dh404, in chronic kidney disease. Free Radic Biol Med 2015; 86: 374-381
43. Miyazaki Y, Shimizu A, Pastan I et al. Keap1 inhibition attenuates glomerulosclerosis. Nephrol Dial Transplant 2014; 29: 783-791
44. Itoh K, Chiba T, Takahashi S et al. An Nrf2 small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322
45. McMahon M, Itoh K, Yamamoto M et al. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 2001; 61: 3299-3307
46. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264
47. Eisenhart C. The assumptions underlying the analysis of variance. Biometrics 1947; 3: 1-21
48. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300
49. R-Development-Core-Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2005
50. van Helden J. Regulatory sequence analysis tools. Nucleic Acids Res 2003; 31: 3593-3596
51. Hayes JD, McMahon M, Chowdhry S et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010; 13: 1713-1748.